Diffuse-type gastric cancer (DGC) in particular demonstrates infiltrative growth, and occasionally metastases to lymph nodes, resulting in worse prognosis.2 Although several clinical trials of chemotherapeutic drugs for advanced GC have been launched, overall survival rates have not been dramatically improved, approximately 20% in 5 years.3–5 Germline mutations of CDH1 are frequently identified in hereditary DGC, while TP53, CDH1 and RHOA mutations in sporadic DGC, but molecular mechanisms underlying diffuse-type gastric carcinogenesis have not been completely clarified.6, 7. This evidence concerns the gene TP53 and gastric cancer.